Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

HER2-Mutant Non-Small Cell Lung Cancer (HER2-mutant NSCLC) is a molecularly defined subset of NSCLC characterized by activating mutations in the ERBB2 gene, most commonly involving the tyrosine kinase domain and exon 20 insertions. Contemporary literature estimates HER2 mutations in approximately 1%-4% of NSCLC overall, although prevalence varies according to population, histology, testing technology, and variant classification. According to HER2-Mutant NSCLC Epidemiology Forecast by Expert Market Research (EMR), assessment therefore requires molecularly confirmed HER2 mutation to be separated from other HER2-altered NSCLC populations.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

HER2-Mutant NSCLC – Number of Cases by Year

Read more about this report - Request a Free Sample

HER2-Mutant NSCLC Epidemiology Forecast Report Coverage

Expert Market Research's “HER2-Mutant NSCLC Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of HER2-Mutant NSCLC. It projects the future incidence and prevalence rates of HER2-Mutant NSCLC cases across various populations. The study covers age, gender, and type as major determinants of the HER2-Mutant NSCLC population. The report highlights patterns in the prevalence of HER2-Mutant NSCLC over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of HER2-Mutant NSCLC in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

HER2-Mutant NSCLC Understanding: Disease Overview

HER2-Mutant Non-Small Cell Lung Cancer (HER2-mutant NSCLC) is a molecularly defined subset of NSCLC characterized by activating mutations in the ERBB2 gene, most commonly involving the tyrosine kinase domain and exon 20 insertions. HER2-mutant NSCLC is predominantly associated with lung adenocarcinoma and occurs disproportionately in women and never or light smokers compared with unselected NSCLC populations. Most activating variants occur in the tyrosine kinase domain, with exon 20 insertions representing the dominant mutation class. The A775_G776insYVMA/p.Y772_A775dup variant is among the most frequently identified alterations. HER2-mutant tumors may exhibit aggressive clinical behavior, frequent metastatic disease, and clinically relevant central nervous system involvement. Recent genomic studies also demonstrate heterogeneity in outcomes according to the precise HER2 mutation and its molecular context.

Key Report Insights

Parameter

Insight

Largest Patient Pool

Japan

Fastest Growing Country

United States

High-Risk Population

Women, never smokers, younger patients, and individuals with lung adenocarcinoma are disproportionately represented among HER2-mutant NSCLC cases. Recent Chinese genomic analyses identify enrichment among women and never smokers, while HER2-mutant disease is also associated with a clinically important risk of brain metastases.

Key Diagnostic Method

Comprehensive NGS is preferred for identifying activating HER2 mutations, while tissue NGS is favored when adequate tissue is available. Validated plasma ctDNA testing can complement tissue testing when tissue is unavailable or inadequate. HER2 IHC alone cannot reliably identify HER2-mutant NSCLC.

Major Risk Factor

Tobacco smoking is the leading modifiable risk factor for NSCLC, while exposure to secondhand smoke, occupational carcinogens, radon, air pollution, prior thoracic radiation, and genetic susceptibility also contribute to lung cancer risk.

Major gap in the market

Major gaps include incomplete molecular testing, limited data on non-exon-20 mutations and CNS treatment, acquired resistance, and few validated therapies for earlier-stage disease. Distinguishing HER2 mutations from amplification and overexpression remains a key diagnostic need.

HER2-Mutant NSCLC Epidemiology Perspective

The HER2-Mutant NSCLC epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the HER2-Mutant NSCLC epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for HER2-Mutant NSCLC and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

HER2 mutations are uncommon but clinically actionable alterations in NSCLC. A 2026 targeted literature review found reported prevalence of 1.6%-4.8% in East Asia, 1.2%-3.9% in Europe, and 1.5%-4.4% in North America, with weighted averages of 3.5%, 1.8%, and 2.0%, respectively. A 2024 LC-SCRUM-Asia analysis identified HER2 mutations in 402 of 15,251 NSCLC patients, corresponding to 2.6%.

Gender-Specific Cases of the Disease

HER2-mutant NSCLC has a marked female enrichment relative to unselected NSCLC. Contemporary molecular reviews consistently identify women as a disproportionately represented population, particularly among never-smoking adenocarcinoma patients. A 2025 South China study found exon 20 mutations were more frequent among men within its HER2-mutant subgroup, demonstrating mutation-specific heterogeneity.

Age-Specific Cases of the Disease

HER2-mutant NSCLC can occur across adulthood but is frequently identified at a younger age than smoking-associated NSCLC. A 2025 South China multicenter study reported a median age of 58.5 years among patients with HER2 alterations. Contemporary Chinese reviews also identify younger age as a recurrent characteristic of HER2-mutant disease, although no standardized age-specific population incidence has been established.

Ethnicity-Wise Cases of the Disease

HER2 mutation prevalence differs geographically. The 2026 targeted literature review reported weighted prevalence of 3.5% in East Asia, 1.8% in Europe, and 2.0% in North America. Chinese NGS cohorts from 2019-2024 reported 3.8%-5.6%, while Japanese and Korean cohorts generally ranged from 2.1%-4.2%. These differences reflect both population biology and substantial variation in molecular testing methodology and cohort selection.

Mortality and Survival Analysis of the Disease

HER2-mutant NSCLC historically had poor outcomes with conventional systemic treatment, although contemporary HER2-directed therapy has changed the therapeutic landscape. A 2025 final DESTINY-Lung02 analysis confirmed durable activity of trastuzumab deruxtecan in previously treated metastatic HER2-mutant NSCLC. Median progression-free survival with the approved 5.4-mg/kg dose was 7.1 months. Prognosis remains heterogeneous according to mutation type, metastatic burden, CNS disease, and subsequent treatment access.

HER2-Mutant NSCLC – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise HER2-Mutant NSCLC Epidemiology

The HER2-Mutant NSCLC epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

Contemporary U.S. genomic datasets have generally reported HER2 mutation frequencies around 1.5%-4.1% depending on cohort and testing platform. A large Flatiron Health-Foundation Medicine dataset included 9,206 NSCLC cases and identified HER2 mutations in 1.9%. HER2 mutation testing is clinically important because activating ERBB2 alterations constitute a therapeutically actionable molecular subgroup of advanced NSCLC.

Germany

European genomic studies generally report HER2 mutation frequencies across a measurable range, with the 2026 targeted review reporting a prevalence of 1.2%–3.9% in Europe and a weighted average of 1.8%. Germany contributes to the growing body of European molecular evidence on HER2-mutant NSCLC, while differences in molecular testing practices and variant classification provide opportunities for further refinement of national epidemiological estimates.

France

Contemporary European datasets provide a useful reference for understanding HER2-mutant NSCLC in France, with European HER2 mutation frequencies generally ranging from 1.2%–3.9%. French patients are represented in European molecular oncology datasets, providing an established evidence base for characterizing HER2-mutant disease. Continued adoption of standardized NGS-based testing can further strengthen country-specific epidemiological assessment.

Italy

Italy is contributing to the growing European evidence base on HER2-mutant NSCLC through molecularly characterized NSCLC cohorts and broader genomic datasets. European studies report HER2 mutation frequencies within the 1.2%–3.9% range, providing a useful benchmark for the Italian population. Increasing adoption of broad genomic profiling in advanced nonsquamous NSCLC is expected to support more comprehensive identification and characterization of patients with actionable HER2 mutations.

Spain

Spain contributes to European molecular profiling datasets that report HER2 mutation frequencies generally within the 1.2%–3.9% range. These findings provide an important epidemiological reference for understanding HER2-mutant NSCLC in the Spanish population. Continued expansion of standardized molecular testing and national genomic data collection can further enhance the characterization of HER2-mutant NSCLC and support more precise patient-population assessment.

United Kingdom

The United Kingdom has established molecular testing pathways for advanced NSCLC, providing an important infrastructure for identifying patients with actionable HER2 mutations. European literature reports HER2 mutation frequencies broadly within the 1.2%–3.9% range, offering a relevant benchmark for the UK population. Increasing access to comprehensive NGS can further strengthen detection of activating HER2 mutations, which cannot be reliably identified through HER2 protein expression alone.

Japan

Japanese and Korean cohorts generally report HER2 mutation prevalence of approximately 2.1%-4.2%. The 2024 LC-SCRUM-Asia analysis identified HER2 mutations in 402 of 15,251 NSCLC patients, or 2.6%, across a large Asian molecular database. Earlier Japanese genomic cohorts included in contemporary reviews have reported approximately 2.7%-4.9%, demonstrating persistent variation by assay and population.

India

Contemporary Indian population-level data remain limited. A 2024 systematic review identified HER2 exon 20 insertions at approximately 1.5% in one Indian NSCLC dataset, but the evidence base is substantially smaller than for East Asia, North America, or Europe. Consequently, this figure should not be extrapolated into a national prevalence estimate. Expanded NGS access is important for identifying Indian patients with actionable HER2 mutations.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The principal epidemiological gap in HER2-mutant NSCLC is not simply the rarity of the alteration but the absence of standardized molecular ascertainment across populations. Contemporary studies report approximately 1%-4% prevalence overall, with weighted regional estimates of 3.5% in East Asia, 1.8% in Europe, and 2.0% in North America. Differences arise from sequencing platforms, inclusion of variants of uncertain significance, tissue versus plasma testing, cohort selection, and whether all ERBB2 mutations or only oncogenic alterations are counted. The distinction is clinically important because HER2 amplification and HER2 protein overexpression are not interchangeable with activating HER2 mutation. Broader NGS implementation therefore has the potential to identify patients missed by limited biomarker testing.

HER2-Mutant NSCLC: Treatment Overview

Management of HER2-mutant NSCLC is centered on molecularly guided systemic therapy. Trastuzumab deruxtecan (T-DXd) remains the principal approved HER2-directed therapy for unresectable or metastatic NSCLC with activating HER2 mutations following prior systemic treatment in the United States. Current prescribing information specifies a dose of 5.4 mg/kg intravenously every three weeks. F Final DESTINY-Lung02 results reported a median progression-free survival of 10.0 months with the approved 5.4 mg/kg dose. Treatment requires monitoring for interstitial lung disease/pneumonitis, cytopenias, nausea, and other adverse events. Platinum-based chemotherapy and immunotherapy may be used according to disease setting and prior treatment, although their activity in HER2-mutant tumors is less predictable than in some other molecularly defined NSCLC populations.

Key Questions Answered

  • What is the current and projected burden of HER2-Mutant NSCLC across the 8 major markets?
  • Which countries across the 8 major markets account for the highest HER2-Mutant NSCLC patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of HER2-Mutant NSCLC across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of HER2-Mutant NSCLC across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of HER2-Mutant NSCLC across the 8 major markets?
  • How do major comorbidities and risk factors influence HER2-Mutant NSCLC epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of HER2-Mutant NSCLC across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the HER2-Mutant NSCLC landscape across the 8 major markets?
  • Which therapeutic areas linked to HER2-Mutant NSCLC are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the HER2-Mutant NSCLC epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on HER2-Mutant NSCLC epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for HER2-Mutant NSCLC across the 8 major markets?

Scope of the HER2-Mutant NSCLC Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of HER2-Mutant NSCLC based on several factors.
  • HER2-Mutant NSCLC Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The HER2-Mutant NSCLC report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

HER2 Non-Small Cell Lung Cancer Epidemiology Forecast

Lung Cancer Therapeutics Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us